BioAscent To Launch New Compound Cloud Library Service, Increasing Drug Discovery Success
BioAscent launches a ‘Spotify’ for Drug Discovery
Spotify is known for offering consumers affordable, customisable access to a large music library, allowing people to enjoy the music they want, when they want it, without having to listen to every track on the album.
Now, Scottish compound management company BioAscent is launching ‘Compound Cloud’ – which they describe as ‘the Spotify of the drug discovery world’.
Organisations involved in the search for new drugs need a range of chemical compounds to test against their biological assays. In the past, these organisations were faced with either creating their own compounds, which is costly and time consuming, or buying fixed sets of compounds in large amounts, inevitably leading to wastage.
Compound Cloud offers affordable, customisable access to an IP-free former pharma compound library of chemicals, available in much smaller individual quantities. This will allow drug discovery organisations to potentially discover much more within a fraction of the time and at a lower cost.
Brand new to the market, this important new service will enable customers to have complete control over the content and format of their compound library to fit their exact needs - eliminating wastage and reducing storage space by offering ‘just in time’ global delivery of pre-plated sets containing just enough compound for an assay.
BioAscent predicts that high demand for this service will increase turnover for this part of their company by 300 percent over the next year, with three quarters of orders coming from overseas markets, including Europe, the USA and Canada.
Simon MacKenzie, BioAscent’s CEO said: “Compound Cloud was created after gathering extensive feedback from our customers. It provides simple, rapid and flexible access to quality compound libraries for drug discovery. It will allow customers to have complete control over their compound library, using our library as if it were their own.”
Glenn Crocker, Chief Executive of BioCity Group added: “Around 35% of early stage drug discovery projects in both industry and academia fail at the hit stage due to the poor structural properties of the compounds found through biological testing, which means there is no value to progressing these any further. This can be hugely frustrating for all involved, after what can be years of biological work. Compound Cloud is an exciting development which will help improve companies’ chances of drug discovery success, which is good news not just for the companies but for healthcare in general.”
Compound Cloud can be accessed online at: www.compoundcloud.com
ENDS
Notes to editors
BioAscent
BioAscent was formed in 2014 as part of the BioCity Group. It provides storage, logistics and delivery of chemicals to the pharmaceutical industry, biotech companies and academics across the globe.
BioAscent delivers access to new, diverse compound collections through:
- Customisable access to an IP-free, former pharma companies lead-like, medicinal chemist selected, compound library.
- Access to novel collections being offered by other drug discovery organisations
- Facilitating the secure sharing of partner collections between pharma, biotech and academic institutions, such as the Pierre Fabre Open Nature Library, using our industrial standard compound storage and IT systems.
In addition, BioAscent operates a compound management, logistics and worldwide shipping service from our modern compound management facility, originally designed to serve the global needs of MSD. BioAscent’s services allow the value of existing compound collections to be maximised, improving the way they are used, and increasing collection lifespan and quality.
Further information on our services can be found at www.bioascent.com
BioCity Scotland
BioCity Scotland has a key role to play in creating new companies, job opportunities, health and wealth benefits and creating the perfect environment for inward investment opportunities, integrating them quickly into the Scottish life sciences community.
• BioCity already has more space occupied than any other incubator in Scotland – with lots of room to grow.
• BioCity Scotland provides fully fitted laboratory space for companies of all sizes – from university spin outs to later stage companies wanting to expand their operations.
Spotify is known for offering consumers affordable, customisable access to a large music library, allowing people to enjoy the music they want, when they want it, without having to listen to every track on the album.
Now, Scottish compound management company BioAscent is launching ‘Compound Cloud’ – which they describe as ‘the Spotify of the drug discovery world’.
Organisations involved in the search for new drugs need a range of chemical compounds to test against their biological assays. In the past, these organisations were faced with either creating their own compounds, which is costly and time consuming, or buying fixed sets of compounds in large amounts, inevitably leading to wastage.
Compound Cloud offers affordable, customisable access to an IP-free former pharma compound library of chemicals, available in much smaller individual quantities. This will allow drug discovery organisations to potentially discover much more within a fraction of the time and at a lower cost.
Brand new to the market, this important new service will enable customers to have complete control over the content and format of their compound library to fit their exact needs - eliminating wastage and reducing storage space by offering ‘just in time’ global delivery of pre-plated sets containing just enough compound for an assay.
BioAscent predicts that high demand for this service will increase turnover for this part of their company by 300 percent over the next year, with three quarters of orders coming from overseas markets, including Europe, the USA and Canada.
Simon MacKenzie, BioAscent’s CEO said: “Compound Cloud was created after gathering extensive feedback from our customers. It provides simple, rapid and flexible access to quality compound libraries for drug discovery. It will allow customers to have complete control over their compound library, using our library as if it were their own.”
Glenn Crocker, Chief Executive of BioCity Group added: “Around 35% of early stage drug discovery projects in both industry and academia fail at the hit stage due to the poor structural properties of the compounds found through biological testing, which means there is no value to progressing these any further. This can be hugely frustrating for all involved, after what can be years of biological work. Compound Cloud is an exciting development which will help improve companies’ chances of drug discovery success, which is good news not just for the companies but for healthcare in general.”
Compound Cloud can be accessed online at: www.compoundcloud.com
ENDS
Notes to editors
BioAscent
BioAscent was formed in 2014 as part of the BioCity Group. It provides storage, logistics and delivery of chemicals to the pharmaceutical industry, biotech companies and academics across the globe.
BioAscent delivers access to new, diverse compound collections through:
- Customisable access to an IP-free, former pharma companies lead-like, medicinal chemist selected, compound library.
- Access to novel collections being offered by other drug discovery organisations
- Facilitating the secure sharing of partner collections between pharma, biotech and academic institutions, such as the Pierre Fabre Open Nature Library, using our industrial standard compound storage and IT systems.
In addition, BioAscent operates a compound management, logistics and worldwide shipping service from our modern compound management facility, originally designed to serve the global needs of MSD. BioAscent’s services allow the value of existing compound collections to be maximised, improving the way they are used, and increasing collection lifespan and quality.
Further information on our services can be found at www.bioascent.com
BioCity Scotland
BioCity Scotland has a key role to play in creating new companies, job opportunities, health and wealth benefits and creating the perfect environment for inward investment opportunities, integrating them quickly into the Scottish life sciences community.
• BioCity already has more space occupied than any other incubator in Scotland – with lots of room to grow.
• BioCity Scotland provides fully fitted laboratory space for companies of all sizes – from university spin outs to later stage companies wanting to expand their operations.